GE HealthCare to acquire Sofie Biosciences for $945 million

· Health · United States

GE HealthCare agreed to acquire Sofie Biosciences for $945 million, a purchase that expands the company's radiopharmaceutical capabilities. Sofie Biosciences specializes in manufacturing and distributing time-sensitive drugs used in PET imaging, a category of radiopharmaceuticals that must be produced and delivered quickly because of their short half-lives. The deal adds to GE HealthCare's portfolio in molecular imaging, where it already sells PET scanners, and gives it more control over the supply of the diagnostic agents those scanners rely on. Radiopharmaceuticals have become an increasingly competitive area of medical imaging, and owning production and distribution capacity can be a strategic advantage because of the logistical constraints on these products.

Why it matters：The deal reflects consolidation in radiopharmaceuticals, where control of short-lived diagnostic agents' production and distribution is becoming a competitive edge in molecular imaging.

Key points

  • The purchase price is $945 million.
  • Sofie Biosciences makes and distributes PET imaging drugs.
  • The acquisition expands GE HealthCare's radiopharmaceutical capabilities.

Sources (original reporting)

More stories from this day